




### **CSIRO** in Australia





CSIRO is a Federal Government Agency.

Its annual budget of over \$900 million comes from the Federal Government and external sources.



CSIRO's research spans agriculture, food, environment, manufacturing industry, minerals, energy, information technology, health, infrastructure and services.











## **CSIRO's Mission Statement & Strategy**


"By igniting the creative spirit of our people, we deliver great science and innovative solutions for industry, society and the environment."







### **CSIRO** across Australia







### **CSIRO Molecular & Health Technologies: CMHT**

- 4 Laboratories; 320 staff; multidisciplinary skills base
  - Melbourne
    - Clayton: synthetic chemistry, polymers, materials
    - Parkville: protein chemistry
  - Sydney (North Ryde): molecular and cellular biology
  - Adelaide: toxicology, animal models
- Access to Major Facilities
  - Australian Synchrotron (Clayton)
  - OPAL reactor (Menai)







#### **CMHT Themes**

- Biomaterials and Regenerative Medicine
  - The development and application of novel biodegradable and bioactive biomaterials suitable for the repair, replacement and regeneration of diseased or damaged body parts.
- Electroactive Materials
  - The development of new platform technologies for polymer electronics.
- Australian Biotech Growth Partnerships
  - Supporting Australian biotech SMEs, particularly in the agricultural and health biotech sectors.
- Nanobiotechnology-Sensing & Delivery
  - Development of smart nanomaterials with in-built biological functionality for targeted bioactive delivery and diagnostics



#### **CMHT Achievements**









dr manny noakes with dr peter clifton

# the CSIRO total wellbeing

- the weight loss program that can actually work diet
- . a healthy eating plan for life

the new scientifically proven diet for Australians





#### **CSIRO** and CMHT Research Focus

CSIRO's research is focused and delivered in three major areas:

- Priority-driven core research
- National Research Flagships
- The Emerging Science Initiative (ESI)

Hierarchical Material Structures: Creating Novel 3-D Porous Particulate Systems by Developing Combinatorial and High-Throughput Methodologies



#### **NIST-CSIRO Collaboration**

High-through put characterisation of multicomponent complex systems (phase behaviour)

In the quest to rationally design advanced materials the challenge remains to deconvolute the relationship between structure, composition and function.





### **NIST-CSIRO** Collaboration

# High-through put characterisation for surfactant phase behaviour

- Phase diagrams contain the complete information on the thermodynamic and kinetic phase behaviour of a system in the most compact form.
- Phase diagrams of complex systems are, extremely scarce, largely due to the huge amount of tedious and painstaking work required to collect the data.
- A key scientific challenge is to reduce the time required to generate a phase diagram from weeks to a day or less.



## **CMHT-Philosophy for Mesophase Development**

Devise Novel Surfactant Structures based on empirical literature observation and semi – empirical theory

**Re-engineer structures** 

**Synthesise** 

Screen Phase Behaviour Temperature ranges, phases etc.






## **Surfactant Self Assembly**




They Spontaneously accumulate at interfaces, lowering interfacial tension

At higher concentrations, they self assemble in solution to form spherical aggregates: micelles

Further complex structures may form depending on molecular geometry and environmental conditions (temperature, concentration, salt etc.) = "Surfactant Phase Behaviour"






Surfactant Mesophase Structures






## **Mesophase Systems**

Inverse **Hexagonal Phases** 



### Inverse **Cubic Phases**





- Bicontinuous networks
- ✓ Containment of aqueous and/or non polar species
- ✓ Unique 'nanoenvironments' for solubilization
- High Tortuosity for release
- √ 3-D high capacity for solutes (cf. liposomes)
- Stability against dilution & rupture proof




### **Dilutable Phase Behaviour**


#### Glycerol Monooleate (Monoolein)





#### **Phytantriol**






Qui and Caffrey, *Biomaterials*, 21, 2000, 223-234

Barauskas and Landh, *Langmuir*, 19, 2003, 9562-9565



## **Inverse Phases: Wedge Shaped Molecules**




To obtain high (-) interfacial curvature wedge shaped molecules with relatively small head group area and large chain cross sectional area are required.



#### **Strategies for increasing CPP include:**


- branching (positional isomerism)
- unsaturation
- multiple hydrophobe attachment



Monoolein




## **Engineered Mesophases**




Urea

Fong and Drummond et. al. Chem. Mater., 18, 594-597, 2006 Fong and Hartley et. al. Aust. J. Chem., 58, 683-687, 2005 Boyd, B.B., et. al. PCT WO 2004/022530A1






## **Engineered Mesophases**




LPM oleyl glycerate



Colloidosomes




## **Drug Release from Engineered Mesophases**



- Sustained release of anti-cancer agents irinotecan base/HCI (hydrophilic) and paclitaxel (lipophilic) from bulk phase of Oleyl glycerate. This suggests potential for depot formulations.
- b) Encapsulation does not alter phase behaviour




## **Polyvalent Mesophases**



- Polyvalent ligands incorporated as co-surfactants to 'mop up' receptor sites to block adverse cellular interaction (eg. ricin)
- High density of surface binding sites
- In diffusion and entrapment within mesophase



## **Polyvalent Mesophases for Ricin Remediation**



**Phytanol** 





## **Surfactant Mesophases for Bioaffinity Separations**

Composition	% Ricin Removed
Phytantriol (Control)	8.6
Inverse Hexagonal Mesophase Mixtures	
40% Galactose-6-phytanoate/ Phytanyl glycerate	12.2
50% Phytanyl β-1-galactoside/ Phytanyl glycerate	22.4
20% Oleyl α-1-galactoside / Oleyl Glycerate	39.6
Inverse Cubic Mesophase Mixtures	
40% Galactose-6-oleate/Oleyl glycerate	40.5
40% Oleyl α-1-galactoside / 60% oleyl glycerate	80.3
40% Oleyl β-1-galactoside/Oleyl glycerate	85.1
40% Phytanyl β-1-galactoside / 60% Phytantriol	90.3
30% Oleyl α-1-galactoside / phytantriol	91.3

Dawson, R.; et. al. Journal of Applied Toxicology (Published online on 17th Feb 2006)





## Acknowledgements

#### **CSIRO Molecular & Health Technologies**

Patrick Hartley Irena Krodkiewska Darrell Wells Tash Polyzos Jamie Booth Calum Drummond Russell Tait

#### **MaynePharma**

Ben Boyd Greg Davey Mei Khoo Micheal Robertson Darryl Whittaker Annette Murphy

## **University of Queensland Alasdair McDowall**

#### **DSTO**

Mike Alderton Ray Dawson

#### **NIST-NCMC**

Eric Amis Michael Fasolka Kathryn Beers Tom Chastek Susan Barnes Kirt Page





## **CSIRO: People & Infrastructure**

- CSIRO ranks in the top 1% of world scientific institutions in 11 of 22 research fields
- 60% of our staff hold university degrees
  - >1800 doctorates
  - > 430 masters' degrees
- Citations per publication are 30% above world average
- More than 160 companies are based on CSIRO intellectual property










## **Physico-Chemical Characterisation**


Water penetration scans: Light polarising microscopy





### Small Angle Scattering -SAS




















Incubate with Mesophase



Take supernatant, incubate with asialofetuin



IgG - AP Rabbit Anti-ricin

Wash and probe with ELISA, Correlate wrt. [ricin] calibration curve

Dawson et. Al.. J. Appl. Toxicol. 19, 307-312 (1999)





## **Bicontinuous Cubic Phases**

